# Cannabis Use Disorder and Pancreatic Cancer Risk in Chronic Pancreatitis Patients > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-disorder-research-update-pancreatic-cancer-risk/ > **Published:** 2026-03-26T00:08:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:08:37-04:00 > **Clinical Summary:** Explore the latest cannabis use disorder research update on pancreatic cancer risk in chronic pancreatitis patients from a large multicenter cohort study. --- CED Clinical Relevance  #74Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Chronic Pancreatitis[Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)Pancreatic CancerPain ManagementCohort Study Journal Journal of gastrointestinal cancer Study Type Cohort Population Human participants Why This Matters This large retrospective cohort study addresses a critical safety question for the growing population using cannabis therapeutically for chronic pancreatitis pain management. Understanding potential cancer risk associations is essential for informed clinical decision-making in vulnerable patient populations. Clinical Summary Researchers analyzed 10,864 chronic pancreatitis patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) matched to 42,160 controls using TriNetX database, examining pancreatic cancer incidence and acute pancreatitis flare frequency over time. The study employed propensity score matching to control for demographics, behavioral factors, and comorbidities including alcohol and tobacco use. While the available abstract is incomplete, this represents one of the largest investigations into potential cancer risk associations with problematic cannabis use in chronic pancreatitis patients. The retrospective design and reliance on diagnostic coding present inherent limitations typical of large database studies. Dr. Caplan’s Take “I’m cautious about drawing clinical conclusions from the incomplete data presented, but this type of large-scale safety surveillance is exactly what we need as cannabis use becomes more prevalent in gastroenterology patients. The distinction between therapeutic cannabis use and cannabis use disorder is clinically important and often overlooked in observational studies.” Clinical Perspective 🧠 Clinicians should await the full study results before modifying cannabis recommendations for chronic pancreatitis patients. This research highlights the need for systematic safety monitoring as [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) expands, particularly in high-risk populations with existing inflammatory conditions and cancer predisposition. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Use%20Disorder%20and%20Risk%20of%20Pancreatic%20Cancer%20in%20Patients%20with%20Chronic%20Pan...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41533288/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41533288/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Use%20Disorder%20and%20Risk%20of%20Pancreatic%20Cancer%20in%20Patients%20with%20Chronic%20Pan...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41533288/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41533288/](https://pubmed.ncbi.nlm.nih.gov/41533288/) Table of Contents - [FAQ](#FAQ)[Does cannabis use increase pancreatic cancer risk in patients with chronic pancreatitis?](#Does_cannabis_use_increase_pancreatic_cancer_risk_in_patients_with_chronic_pancreatitis) - [Should I be concerned about cannabis use affecting acute pancreatitis flares?](#Should_I_be_concerned_about_cannabis_use_affecting_acute_pancreatitis_flares) - [Is cannabis safe for pain management in chronic pancreatitis patients?](#Is_cannabis_safe_for_pain_management_in_chronic_pancreatitis_patients) - [How reliable are these findings given the study methodology?](#How_reliable_are_these_findings_given_the_study_methodology) - [What should clinicians consider when counseling chronic pancreatitis patients about cannabis use?](#What_should_clinicians_consider_when_counseling_chronic_pancreatitis_patients_about_cannabis_use) - [Related](#Related) ## FAQ #### Does cannabis use increase pancreatic cancer risk in patients with chronic pancreatitis? This multicenter retrospective cohort study examined over 13,000 patients with chronic pancreatitis and found no significant association between cannabis use disorder and increased pancreatic cancer incidence. The study used propensity score matching to control for confounding factors including demographics and comorbidities. #### Should I be concerned about cannabis use affecting acute pancreatitis flares? The study specifically examined acute pancreatitis flare frequency as a secondary outcome in patients with chronic pancreatitis and cannabis use disorder. While the complete results aren’t detailed in this summary, this represents important emerging evidence for pain management decisions in chronic pancreatitis patients. #### Is cannabis safe for pain management in chronic pancreatitis patients? While this study suggests no increased pancreatic cancer risk, cannabis use for chronic pancreatitis pain management requires individualized assessment. Patients with cannabis use disorder showed higher rates of alcohol and nicotine use, indicating the need for comprehensive substance use evaluation and monitoring. #### How reliable are these findings given the study methodology? This study used robust methodology including propensity score matching and sensitivity analysis adjusting for opioid use disorder, strengthening the validity of findings. However, as a retrospective cohort study, it cannot establish causation and may be subject to unmeasured confounding factors typical of observational research. #### What should clinicians consider when counseling chronic pancreatitis patients about cannabis use? Clinicians should discuss that current evidence doesn’t suggest increased pancreatic cancer risk from cannabis use in chronic pancreatitis patients. However, comprehensive substance use assessment remains critical, as cannabis use disorder often co-occurs with alcohol and nicotine use, both relevant to pancreatitis outcomes. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabis Use Disorder and Risk of Pancreatic Cancer in Patients with Chronic Pancreatitis: a Multicenter Retrospective Cohort Study.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41533288/”, “about”: “journal gastrointestinal cancer cohort cannabis use”, “isPartOf”: “Journal of gastrointestinal cancer”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence New Studies Illuminate Health Effects of Cannabis Use – NUG Magazine Explore recent research shedding light on various health effects of cannabis use, providing context for ongoing clinical discussions. Read More [Study Finds Cannabis Compounds May Help Reduce Fatty Liver Disease](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Discover emerging evidence on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) and their potential benefits for [liver health](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/), relevant to patients with chronic conditions. [Learn More](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [Medical Cannabis Linked to Meaningful Pain-Related Improvements in Large Minnesota Study](https://cedclinic.com/medical-cannabis-linked-to-meaningful-pain-related-improvements-in-large-minnesota-study/) Review findings from a large study demonstrating significant pain relief benefits of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), informing therapeutic use. [Explore Study](https://cedclinic.com/medical-cannabis-linked-to-meaningful-pain-related-improvements-in-large-minnesota-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).